To definitively link enhanced Yap activity as the primary mechanism of endothelial dysfunction in Nup93‐deficient human ECs, we introduced verteporfin (VP), a potent pharmacological inhibitor of Yap. Here, NUP93 is linked to endothelial dysfunction.